Acrivon Therapeutics Inc

Acrivon Therapeutics Inc has a market capitalization of $82.18 million and a price-to-book ratio of 0.73, indicating that the company is trading at a discount to its book value. The company's liquidity position is strong, with a current ratio of 7.69, and it holds $41.50 million in cash and equivalents, while having no long-term debt. The company's equity base is $112.52 million, and its total liabilities are relatively low at $17.20 million. The company's profitability is currently negative, with a net loss of $77.91 million and an operating loss of $84.11 million in the latest period. Its return on equity is -69.24%, and its return on assets is -60.06%, both significantly below the industry median for biotechnology firms. The company's operating cash flow is negative at -$63.67 million, and its free cash flow is -$78.17 million, indicating that it is not generating positive cash from operations. Acrivon Therapeutics Inc is a single-segment company, with all of its operations focused on the development of respiratory therapeutics. The company does not disclose geographic revenue breakdowns, but its operations are primarily based in the United States. The company's revenue is not disclosed, but its financials suggest it is in the pre-revenue or early-stage development phase. The company's growth trajectory is not yet defined in terms of revenue, as it is not currently generating revenue. However, its capital expenditures of -$1.67 million suggest ongoing investment in development activities. Analysts have assigned a mean price target of $12.25, with a median of $11.00, indicating a potential upside of over 500% from the current market price of $1.92. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no long-term debt and a strong cash position, which reduces its financial risk. However, the company's reliance on equity financing and the absence of revenue introduce operational and dilution risks in the long term. Recent events include the continued development of ACR-161, with no major regulatory or clinical setbacks reported in the latest filings. The company has not issued any new shares in the recent period, and there are no immediate signs of dilution pressure.